To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC78812 | CEB-1604 |
CEB-1604 is an NMDA receptor antagonist. CEB-1604 inhibits NMDA-induced currents in oocytes transfected with NMDA receptor isoforms (NR1/NR2A, NR1/NR2B, NR1/NR2C, NR1/NR2D) with IC50 values ranging from 5 to 12 μM. CEB-1604 abolishes NMDA-dependent epileptiform discharges in rat cortical wedge preparations and reduces the depolarizing effects of NMDA. CEB-1604 can be used in the research field of neurological damage diseases.
More description
|
|
| DC78800 | NAADP tetrasodium |
NAADP tetrasodium is a second messenger. NAADP tetrasodium releases Ca2+ from acidic endosomes and lysosomes. NAADP tetrasodium can be used to study cancer (such as oral squamous cell carcinoma, malignant melanoma) and angiogenesis-related diseases.
More description
|
|
| DC78794 | AL 0671 |
AL 0671 is a potassium channel opener. AL 0671 can inhibit nonenzymatic glycation of protein and LDL oxidation. AL 0671 can be used for the researches of cardiovascular and metabolic disease, such as hypertensive diabetes.
More description
|
|
| DC78791 | BW-4030W92 |
BW-4030W92 is a sodium channel blocker. BW-4030W92 induces ataxia.
More description
|
|
| DC78784 | Aminochalcone 4AAF |
Aminochalcone 4AAF is a neuroprotective agent that exerts anxiolytic effects through GABAA and 5-HT receptors. Aminochalcone 4AAF has high selectivity for 5-HT3A and 5-HT2C receptors, and stimulates allosteric behavior toward the 5-HT2A receptor. Aminochalcone 4AAF shows hypoglycemic effects and reduces the level of ROS in the liver. Aminochalcone 4AAF delays the clonic stage of the epileptic seizures . Aminochalcone 4AAF can be used in the study of anxiety, hyperglycemia, and seizures.
More description
|
|
| DC78725 | BMS-182264 |
BMS-182264 is a highly selective ATP-sensitive potassium channel agonist. BMS-182264 promotes potassium efflux and membrane hyperpolarization to induce smooth muscle relaxation and vasodilation. BMS-182264 is promising for research of cardiovascular diseases such as hypertension and myocardial ischemia.
More description
|
|
| DC78724 | KI 1769 |
KI 1769 is a potassium channel opener. KI 1769 can exhibit vasodilating effect. KI 1769 prolongs the micturition interval and reduces the resistance to fluid infusion through the urethral lumen. KI 1769 can be used for the research of cardiovascular disease.
More description
|
|
| DC78684 | Fluorolintane |
Fluorolintane exhibits high affinity for N-methyl-D-aspartate (NMDA) receptors with a Ki of 87.92 nM. Fluorolintane inhibits prepulse inhibition in rats. Fluorolintane also inhibits NMDA receptor-induced field excitatory postsynaptic potentials in rat hippocampal slices.
More description
|
|
| DC78660 | HW091077 |
HW091077 is a highly selective P2X3 receptor antagonist with an IC50 of 17 nM. HW091077 blocks ATP-induced calcium influx and cell depolarization to inhibit cough reflex pathways. HW091077 is promising for research of chronic cough.
More description
|
|
| DC78658 | Padoprazanum fumarate |
Padoprazanum (Padoprazan) fumarate is a Proton Pump inhibitor.
More description
|
|
| DC78657 | Padoprazanum hydrochloride |
Padoprazanum (Padoprazan) hydrochloride is a Proton Pump inhibitor.
More description
|
|
| DC78603 | UK-315716 |
UK-315716 is an NMDA receptor antagonist. UK-315716 has a synergistic neuroprotective effect. UK-315716 can be used for research on neurological diseases such as stroke and headache.
More description
|
|
| DC78601 | SIB 1663 |
SIB 1663 is a conformationally restricted analog of nicotine. SIB-1663 selectively activatedα2β4 and α4β4 human recombinant neuronal nAChRs. SIB 1663 can increase DA and NE release. SIB 1663 can be used for the research of neurological disease.
More description
|
|
| DC78589 | SKF-96365 |
SKF-96365 is a blocker of calcium store-operated calcium influx (SOCE) and transient receptor potential channels (TRPC). SKF-96365 reduces the increase in intracellular calcium concentration by blocking TRPC channels and SOCE. SKF-96365 enhances the reverse operation of Na⁺/Ca²⁺ exchanger (NCX) (Ca²⁺ influx) in glioblastoma, leading to intracellular calcium overload and cytotoxicity. SKF-96365 inhibits the CaMKIIγ/AKT pathway and simultaneously induces apoptosis and cell protective autophagy in colorectal cancer cells. SKF-96365 can be used in calcium signaling and cancer research.
More description
|
|
| DC78588 | UK-78282 |
UK-78282 is a selective Kv1.3 voltage-gated potassium channel inhibitor with an IC50 of 200 nM. UK-78282 also inhibit Kv1.4 potassium channel. UK-78282 can inhibit human T cell activation.
More description
|
|
| DC78580 | VU6080824 hydrochloride |
VU6080824 (hydrochloride), a derivative of ML-133), is an inward-rectifier potassium channel (Kir2.1) inhibitor with an IC50 of 0.35 μM. VU6080824 (hydrochloride) has superior thallium flux and manual patch clamp (MPC) functional potency.
More description
|
|
| DC78579 | VU6080824 |
VU6080824 (Compound 5s), a derivative of ML-133), is an inward-rectifier potassium channel (Kir2.1) inhibitor with an IC50 of 0.35 μM. VU6080824 has superior thallium flux and manual patch clamp (MPC) functional potency.
More description
|
|
| DC78547 | E0199 |
E0199 is a novel potent dual-target KV7/NaV modulator that activates the KV7 channel (KV7.2/7.3 (EC50 = 12.78 nM), KV7.2 (EC50 = 0.50 μM), and KV7.5 (EC50 = 27.14 nM) channels) while simultaneously blocks the NaV1.7 (IC50 = 0.52 μM), NaV1.8 (IC50 = 0.24 μM), and NaV1.9 (IC50 = 0.16 μM) channels. E0199 shows a potent analgesic effect without affecting heart and skeletal muscle ion channels critically in a chronic constriction injury (CCI) mouse model. E0199 can be used for Neuropathic pain (NP) research.
More description
|
|
| DC78545 | Eprazole trisulfide dimer |
Eprazole trisulfide dimer is a trisulfide dimer of Ilaprazole), an orally active proton pump inhibitor that irreversibly inhibits H+/K+-ATPase in a dose-dependent manner with an IC50 of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Eprazole trisulfide dimer can be utilized in research on gastric ulcers.
More description
|
|
| DC78517 | Rivanicline hydrochloride |
Rivanicline (RJR-2403) hydrochloride is a neuronal nicotinic receptor agonist. Rivanicline hydrochloride is highly selective for the rat brain cortex nAChRs (Ki = 26 nM, EC50 of 732 nM) and α4β2 subtype (Ki = 26 nM, EC50 = 16 μM). Rivanicline hydrochloride can significantly restore the learning impairment and cognitive dysfunction. Rivanicline hydrochloride can be used for the study of neurodegenerative diseases (such as schizophrenia or Alzheimer's disease).
More description
|
|
| DC78516 | TC-2559 free base |
TC-2559 free base is a α4β2 nicotinic acetylcholine receptor (nAChR) agonists with an EC50 of 0.18 μM. TC-2559 free base shows much weaker potencies on the group of b4-containing nAChR subtypes, α2β4, α4β4 and α3β4 receptors, with EC50s in the range of 10-30 µM. TC-2559 free base can increase the discharge of dopamine cells in the ventral tegmental area (VTA) of rats in vitro, enhancing the excitability and aggressive behavior of VTA dopamine neurons. TC-2559 free base inhibits STAT3 to exert anti-inflammatory properties and relieves mice mechanical allodynia and improve rats cognitive deficits. TC-2559 free base can be used for the study of nerve pain.
More description
|
|
| DC78515 | (E/Z)-Rivanicline |
(E/Z)-Rivanicline ((E/Z)-RJR-2403, (E/Z)-Metanicotine) is the E/Z mixture of Rivanicline). Rivanicline is a neuronal nicotinic receptor (neuronal nicotinic receptor) agonist that is highly selective for the α4β2 subtype, Ki is 26 nM, which is more than 1000 times more inhibitory than α7 receptor.
More description
|
|
| DC78506 | VU0494372 |
VU0494372 is an activator of potassium ion channel KCNQ1. VU0494372 can significantly enhance the cell surface expression and transport efficiency of KCNQ1. VU0494372 does not alter KCNQ1 mRNA levels and protein degradation rate, and has no significant cytotoxicity. VU0494372 can be used for research on cardiovascular conditions.
More description
|
|
| DC78449 | AM-36 |
AM-36 is a neuroprotective agent with combined antioxidant and sodium channel blocking actions. AM-36 can inhibit cell apoptosis and ROS prodiction. AM-36 can reduce neuronal damage and DA release after middle cerebral artery occlusion in rats. AM-36 can be used for the researches of inflammation and neurological disease, such as stroke.
More description
|
|
| DC78409 | Wy 27569 |
Wy 27569 is an orally active vascular selective calcium channel blocker that can effectively lower blood pressure. Wy 27569 is a thromboxane synthase inhibitor that can reshape prostaglandin balance, reduce pro thrombotic TXA2, and increase anti thrombotic PGI2. Wy 27569 can be used for research on cardiovascular diseases such as hypertension and angina.
More description
|
|
| DC78398 | MDL 27266 |
MDL 27266 is an orally active NMDA receptor antagonist with neuroprotective effect. MDL 27266 is a broad-spectrum anticonvulsant agent.
More description
|
|
| DC78394 | Zocainone |
Zocainone is an antiarrhythmic agent. Zocainone blocks sodium channels in cardiac tissue, stabilizing the cardiac action potential and reducing abnormal electrical activity. Zocainone is promising for research of cardiac arrhythmias.
More description
|
|
| DC78393 | T 588 |
T 588 is an orally active neuroprotective agent. T 588 can increase acetylcholine release from the frontal cortex and hippocampus and meliorate cognitive dysfunction. T 588 can protect cerebellar granule cells from glutamate neurotoxicity. T 588can be used for the research of neurological disease, such as Alzheimer's disease.
More description
|
|
| DC78324 | EVT-101 free base |
EVT-101 free base is a GluN2B antagonist. EVT-101 free base binds at the same GluN1/GluN2B dimer interface as Ifenprodil. EVT-101 free base inhibits calcium influx in chicken-derived cells, with an EC50 of 22 nM. EVT-101 can be used in the research of brain disorders.
More description
|
|
| DC78321 | JNJ-78911118 |
JNJ-78911118 is a potent, brain-penetrant, selective GluN2A antagonist (IC50 = 44 nM). JNJ-78911118 shows >200-fold selectivity against GluN1/2B, 2C and 2D receptors. JNJ-78911118 functions as a negative allosteric modulator (NAM) by insurmountably suppressing glutamate efficacy and reducing glycine potency at GluN1/2A receptors. JNJ-78911118 produces profound pharmacodynamic effects in vivo. JNJ-78911118 can be used for depression research.
More description
|
|